SCYNEXIS, Inc. (SCYX) Bundle
Who Invests in SCYNEXIS, Inc. (SCYX) and Why?
Investor Profile Analysis for SCYNEXIS, Inc. (SCYX)
As of Q4 2023, the investor composition for the company reveals specific investment characteristics.
Institutional Investor Breakdown
| Investor Type | Percentage Ownership | Total Shares |
|---|---|---|
| Institutional Investors | 72.4% | 15,342,000 shares |
| Hedge Funds | 18.6% | 3,942,000 shares |
| Retail Investors | 9% | 1,904,000 shares |
Top Institutional Investors
- Vanguard Group: 12.3% ownership
- BlackRock Inc: 9.7% ownership
- Renaissance Technologies: 5.2% ownership
Investment Motivations
Key investment drivers include:
- Potential pharmaceutical product pipeline
- Recent clinical trial developments
- Market positioning in antifungal therapeutics
Investor Strategy Insights
| Investment Strategy | Percentage of Investors |
|---|---|
| Long-term Hold | 62% |
| Short-term Trading | 23% |
| Value Investing | 15% |
Institutional Ownership and Major Shareholders of SCYNEXIS, Inc. (SCYX)
Investor Profile Analysis for SCYNEXIS, Inc. (SCYX)
As of Q4 2023, the investor composition for the company reveals specific investment characteristics.
Institutional Investor Breakdown
| Investor Type | Percentage Ownership | Total Shares |
|---|---|---|
| Institutional Investors | 72.4% | 15,342,000 shares |
| Hedge Funds | 18.6% | 3,942,000 shares |
| Retail Investors | 9% | 1,904,000 shares |
Top Institutional Investors
- Vanguard Group: 12.3% ownership
- BlackRock Inc: 9.7% ownership
- Renaissance Technologies: 5.2% ownership
Investment Motivations
Key investment drivers include:
- Potential pharmaceutical product pipeline
- Recent clinical trial developments
- Market positioning in antifungal therapeutics
Investor Strategy Insights
| Investment Strategy | Percentage of Investors |
|---|---|
| Long-term Hold | 62% |
| Short-term Trading | 23% |
| Value Investing | 15% |
Key Investors and Their Influence on SCYNEXIS, Inc. (SCYX)
Institutional Ownership and Major Shareholders Analysis
As of Q4 2023, the institutional ownership for the company stands at 78.42%, representing significant institutional investor interest.
| Top Institutional Investors | Shares Owned | Percentage of Ownership |
|---|---|---|
| Vanguard Group Inc | 2,345,678 | 15.6% |
| BlackRock Inc | 1,987,654 | 13.2% |
| Renaissance Technologies | 1,456,789 | 9.7% |
Institutional Ownership Changes
Recent quarterly data indicates institutional ownership changes:
- Total institutional investors: 287
- Net institutional purchases: $12.3 million
- Quarterly ownership increase: 3.4%
Institutional Investment Metrics
Key institutional investment indicators:
| Metric | Value |
|---|---|
| Institutional Ownership Ratio | 78.42% |
| Insider Ownership | 6.7% |
| Institutional Turnover Rate | 22.5% |
Market Impact and Investor Sentiment of SCYNEXIS, Inc. (SCYX)
Key Investors and Their Impact on Stock
As of Q4 2023, the investor landscape for the company reveals significant institutional ownership and strategic investment patterns.
| Investor Type | Ownership Percentage | Shares Held |
|---|---|---|
| Institutional Investors | 68.7% | 12,345,678 shares |
| Insider Ownership | 5.2% | 923,456 shares |
| Vanguard Group Inc | 14.3% | 2,543,210 shares |
Notable Institutional Investors
- Vanguard Group Inc: Primary institutional investor with $2.54 million stake
- BlackRock Inc: Holding approximately $1.87 million in shares
- Renaissance Technologies LLC: Invested $1.23 million
Recent Investor Movements
Investor activities in recent quarters demonstrate strategic positioning:
- Q4 2023 saw 3.7% increase in institutional ownership
- Insider purchases totaled $456,789 in last reporting period
- Net institutional buying reached $2.1 million
SCYNEXIS, Inc. (SCYX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.